NCT00202852View on ClinicalTrials.gov

A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

June 1, 2005

Primary Completion Date

March 1, 2006

Study Completion Date

March 1, 2006

Conditions
Arthritis, Rheumatoid
Interventions
OTHER

Placebo

Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX

DRUG

MTX

Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week

BIOLOGICAL

Infliximab

Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX

DRUG

MTX

3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00202852 - A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED) | Biotech Hunter | Biotech Hunter